FDA approval · Drugs@FDA
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINERcefotetan disodium
NDA065430 ·
FDA approved the original new drug application for CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER on August 9, 2007, sponsored by B BRAUN. FDA marks both products under the application discontinued. FDA’s record shows no approved efficacy supplement on the application since.
- Application
- NDA065430
- Sponsor
- B BRAUN
- Original approval
- Active ingredient
- cefotetan disodium
Browse every approval whose brand starts with C, or the complete response letters FDA has published — the applications it did not approve.
Products under this application
| Ingredient and strength | Form | Route | Marketing status |
|---|---|---|---|
| cefotetan disodium EQ 2GM BASE/VIAL | INJECTABLE | INJECTION | Discontinued |
| cefotetan disodium EQ 1GM BASE/VIAL | INJECTABLE | INJECTION | Discontinued |
What “discontinued” means in FDA’s record
Drugs@FDA marks a product discontinued when it was never marketed, when it has been taken off the market, when it is made only for export, when it is made for military use, or when its approval was withdrawn for a reason other than safety or effectiveness. The record does not say which of those applies to a given product. The word on its own is not evidence that FDA found the drug unsafe.
Source: FDA, Drugs@FDA glossary of terms, under “Discontinued Drug Product”.
Approved efficacy supplements
An efficacy supplement is how a sponsor asks FDA to approve a change that needs clinical evidence — most often a new indication. FDA’s record gives each one a submission number, a date and a review priority. It does not say what any supplement approved, so neither does this page. The approval letter and label for each are on accessdata.fda.gov under the application number.
FDA’s record shows no approved efficacy supplement on this application.
FDA records other approved supplements on this application, by the class code it assigns them: Manufacturing (CMC) 1 · Labeling 1. Those are changes to the label or to how the drug is made rather than new clinical evidence, so they are counted here and not listed.
Source: FDA’s Drugs@FDA application file, via openFDA (export 2026-09-03). Every field on this page comes from that record.
Other approvals to B BRAUN
- June 13, 2011CEFTAZIDIME IN DEXTROSE CONTAINERNDA050823
- May 6, 2010CEFEPIME AND DEXTROSE IN DUPLEX CONTAINERNDA050821
- March 10, 2006CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINERNDA065214
- April 20, 2005CEFTRIAXONE AND DEXTROSE IN DUPLEX CONTAINERNDA050796
- July 29, 2004CEFOTAXIME AND DEXTROSE 2.4% IN PLASTIC CONTAINERNDA050792
- February 21, 2001CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINERNDA050780
An approval date is the start of the question, not the end
What a drug is worth to the company that owns it depends on what else is in the pipeline, how much cash is behind it and who else is running the same trial. FuzeBio reads a biotech end to end on demand — pipeline in plain English, trial design and endpoints, competitors, the cash position, and a valuation with its assumptions on the page. Moderna’s report is open in full, no account.
Open the Moderna reportA complete sample report — nothing held back, no sign-up.